OTC M&A Trend May Be Result Of Too Many Large Players At The Top – Panel
This article was originally published in The Tan Sheet
Executive Summary
A lack of competitive global scale may be one factor fueling the divestiture of OTC units by larger pharma companies
You may also be interested in...
Bristol Consumer Unit Suitors Tasked With Determining Value Of Excedrin
Bristol-Myers Squibb says it will contact potential buyers for its North American Consumer Medicines division "over the coming weeks.
Bayer/Roche Consumer Unit Will Focus On Rx-To-OTC Switch Opportunities
Bayer expects the addition of Roche Consumer Health to bolster the firm's ability to handle future Rx-to-OTC switches
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC